Talon Therapeutics, Inc. 4
4 · Talon Therapeutics, Inc. · Filed Jul 18, 2013
Insider Transaction Report
Form 4
MAIER PAUL V
Director
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2013-07-17−47,000→ 0 totalExercise: $0.77Exp: 2021-04-01→ Common Stock (47,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-07-17−47,000→ 0 totalExercise: $0.91Exp: 2022-02-17→ Common Stock (47,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-07-17−47,000→ 0 totalExercise: $0.64Exp: 2023-01-25→ Common Stock (47,000 underlying) - Disposition to Issuer
Common Stock
2013-07-17−1,750→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2013-07-17−12,500→ 0 totalExercise: $0.76Exp: 2020-02-16→ Common Stock (12,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-07-17−10,000→ 0 totalExercise: $3.60Exp: 2018-03-13→ Common Stock (10,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-07-17−2,500→ 0 totalExercise: $2.92Exp: 2018-06-13→ Common Stock (2,500 underlying) - Disposition to Issuer
Stock Option (right to buy)
2013-07-17−12,500→ 0 totalExercise: $0.56Exp: 2019-02-24→ Common Stock (12,500 underlying)
Footnotes (2)
- [F1]The reporting person received $0.056 per share plus one contingent value right (CVR) per share in accordance with the terms of a Stock Purchase Agreement by and among Talon Therapeutics, Inc., Spectrum Pharmaceuticals, Inc. and Eagle Acquisition Merger Sub, Inc. dated July 16, 2013 (the "Purchase Agreement"). Each CVR represents the right to receive a maximum future cash payment of approximately $0.968 per CVR from Spectrum based upon the achievement of certain sales and regulatory milestones.
- [F2]This stock option was cancelled pursuant to the terms of the Purchase Agreement.